Safety and efficacy of single-agent docetaxel (Taxotere) administered weekly in non-small cell lung carcinoma patients in Korea: An observational study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lim, Sun Min | - |
dc.contributor.author | Park, Byeong Bae | - |
dc.contributor.author | Park, Keun-Chil | - |
dc.contributor.author | Kim, Hoon-Kyo | - |
dc.contributor.author | Lee, Jong Seok | - |
dc.contributor.author | Bae, Sung Hwa | - |
dc.contributor.author | Lee, Seung-Sei | - |
dc.contributor.author | Kang, Jin-Hyoung | - |
dc.contributor.author | Park, Se-Hoon | - |
dc.contributor.author | Lee, Gyeong-Won | - |
dc.contributor.author | Lee, Hyo-Rac | - |
dc.contributor.author | Seo, Jae Hong | - |
dc.contributor.author | Kim, Yong Tae | - |
dc.contributor.author | Yang, Sung Hyun | - |
dc.contributor.author | Kim, Joo-Hang | - |
dc.date.accessioned | 2021-09-04T02:09:40Z | - |
dc.date.available | 2021-09-04T02:09:40Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2016-03 | - |
dc.identifier.issn | 1759-7706 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/89354 | - |
dc.description.abstract | BackgroundTo investigate the efficacy, safety, and tolerability of weekly docetaxel treatment in advanced non-small cell lung cancer (NSCLC) patients in Korea. MethodsThis prospective observational study included Korean advanced NSCLC patients with Eastern Cooperative Oncology Group performance status <2 who received weekly monotherapy of docetaxel at a dose determined by the physician. Efficacy measurements included tumor response rate, overall survival (OS), progression-free survival, and one-year survival rate. Safety was analyzed through recorded incidences of adverse events (AEs), serious adverse events (SAEs), deaths, and other related safety parameters, along with their toxicity grades. Results:Of 274 patients analyzed, one patient achieved a complete response and 42 partial responses; thus, the overall response rate was 15.7%. The OS rate at baseline and at one-year follow-up was 38.3% and 33.8%, respectively. AEs were reported in 229 (83.6%) patients. The most frequently reported hematologic AE of grade 3 was a decrease in neutrophils, with 6.6% of the patients developing neutropenia. In non-hematologic AEs of grade 3, the most common were infection with unknown absolute neutrophil count and death not associated with Common Terminology Criteria for Adverse Events (CTCAE) (4.7% each). The most common SAE reported was death, not associated with CTCAE (7.3%). ConclusionsIn Korean patients, the weekly regimen of docetaxel monotherapy was safe and efficacious against advanced NSCLC. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY-BLACKWELL | - |
dc.subject | RANDOMIZED PHASE-III | - |
dc.subject | PLATINUM-BASED CHEMOTHERAPY | - |
dc.subject | ONCOLOGY-GROUP TRIAL | - |
dc.subject | CANCER GROUP TRIAL | - |
dc.subject | EVERY 3 WEEKS | - |
dc.subject | ELDERLY-PATIENTS | - |
dc.subject | 2ND-LINE CHEMOTHERAPY | - |
dc.subject | 3-WEEKLY DOCETAXEL | - |
dc.subject | PLUS CARBOPLATIN | - |
dc.subject | THERAPY | - |
dc.title | Safety and efficacy of single-agent docetaxel (Taxotere) administered weekly in non-small cell lung carcinoma patients in Korea: An observational study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Seo, Jae Hong | - |
dc.identifier.doi | 10.1111/1759-7714.12315 | - |
dc.identifier.scopusid | 2-s2.0-84959545654 | - |
dc.identifier.wosid | 000372281300007 | - |
dc.identifier.bibliographicCitation | THORACIC CANCER, v.7, no.2, pp.207 - 214 | - |
dc.relation.isPartOf | THORACIC CANCER | - |
dc.citation.title | THORACIC CANCER | - |
dc.citation.volume | 7 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 207 | - |
dc.citation.endPage | 214 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Respiratory System | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Respiratory System | - |
dc.subject.keywordPlus | RANDOMIZED PHASE-III | - |
dc.subject.keywordPlus | PLATINUM-BASED CHEMOTHERAPY | - |
dc.subject.keywordPlus | ONCOLOGY-GROUP TRIAL | - |
dc.subject.keywordPlus | CANCER GROUP TRIAL | - |
dc.subject.keywordPlus | EVERY 3 WEEKS | - |
dc.subject.keywordPlus | ELDERLY-PATIENTS | - |
dc.subject.keywordPlus | 2ND-LINE CHEMOTHERAPY | - |
dc.subject.keywordPlus | 3-WEEKLY DOCETAXEL | - |
dc.subject.keywordPlus | PLUS CARBOPLATIN | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | Carcinoma | - |
dc.subject.keywordAuthor | docetaxel | - |
dc.subject.keywordAuthor | non-small cell lung cancer | - |
dc.subject.keywordAuthor | safety | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.